Hypoglycemia – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia – Drugs in Development, 2021, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 2, 2, 1 and 2 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).

– The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Adocia SAS

Avolynt Inc

Covis Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

LATITUDE Pharmaceuticals Inc

Protomer Technologies Inc

Rezolute Inc

USV Pvt Ltd

Zealand Pharma AS

Zosano Pharma Corp

Zucara Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypoglycemia - Overview

Hypoglycemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoglycemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoglycemia - Companies Involved in Therapeutics Development

Adocia SAS

Avolynt Inc

Covis Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

LATITUDE Pharmaceuticals Inc

Protomer Technologies Inc

Rezolute Inc

USV Pvt Ltd

Zealand Pharma AS

Zosano Pharma Corp

Zucara Therapeutics Inc

Hypoglycemia - Drug Profiles

avexitide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVO-3235 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasiglucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rescue-G - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RZ-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoglycemia - Dormant Projects

Hypoglycemia - Discontinued Products

Hypoglycemia - Product Development Milestones

Featured News & Press Releases

Feb 23, 2021: Eiger announces publication of phase 2 PREVENT study results of Avexitide in post-bariatric hypoglycemia in Journal of Clinical Endocrinology & Metabolism

Dec 15, 2020: Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI)

Nov 02, 2020: Zucara Therapeutics expands ZT-01 development program to type 2 diabetes

Sep 29, 2020: Zucara Therapeutics doses first subject in phase 1 trial of ZT-01

Jun 14, 2020: Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association

May 22, 2020: Zealand Pharma announces FDA acceptance of new drug application for the dasiglucagon HypoPal rescue pen for treatment of severe hypoglycemia

Mar 31, 2020: Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal Rescue Pen for treatment of severe hypoglycemia

Mar 30, 2020: Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery

Sep 26, 2019: Zealand reports results of paediatric Phase 3 trial for hypoglycaemia

Jun 17, 2019: Eiger announces breakthrough therapy designation granted by FDA for Avexitide for treatment of Post-Bariatric Hypoglycemia (PBH)

Jun 10, 2019: Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)

May 14, 2019: Zealand announces confirmatory Phase III results in hypoglycaemia

Mar 25, 2019: Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019

Mar 07, 2019: Zealand Pharma begins dosing in Phase III trial for CHI

Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hypoglycemia, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Hypoglycemia – Pipeline by Adocia SAS, 2021

Hypoglycemia – Pipeline by Avolynt Inc, 2021

Hypoglycemia – Pipeline by Covis Pharmaceuticals Inc, 2021

Hypoglycemia – Pipeline by Eiger BioPharmaceuticals Inc, 2021

Hypoglycemia – Pipeline by LATITUDE Pharmaceuticals Inc, 2021

Hypoglycemia – Pipeline by Protomer Technologies Inc, 2021

Hypoglycemia – Pipeline by Rezolute Inc, 2021

Hypoglycemia – Pipeline by USV Pvt Ltd, 2021

Hypoglycemia – Pipeline by Zealand Pharma AS, 2021

Hypoglycemia – Pipeline by Zosano Pharma Corp, 2021

Hypoglycemia – Pipeline by Zucara Therapeutics Inc, 2021

Hypoglycemia – Dormant Projects, 2021

Hypoglycemia – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Hypoglycemia, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Top Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports